Blog
RSS FeedPosted by Michael Wonder on 10 Oct 2016
Life-extending lung cancer drug approved for use in Scotland
10 October 2016 - Scotland has become the first part of the UK to approve a new life-extending treatment for ...
Posted by Michael Wonder on 10 Oct 2016
SMC - October 2016 decisions
10 October 2016 - New treatments for thyroid cancer and lung cancer among five medicines accepted for routine use by ...
Posted by Michael Wonder on 10 Oct 2016
Panadol Osteo price hike statement ambiguous but not misleading: ACCC
10 October 2016 - Statements linking a price increase of Panadol Osteo to its removal from the Pharmaceutical Benefits Scheme were ...
Posted by Michael Wonder on 10 Oct 2016
New electronic portal for bidding on PHARMAC’s annual tender
10 October 2016 - New e-portal for PHARMAC’s annual tender now available to trial. ...
Posted by Michael Wonder on 09 Oct 2016
Leading rheumatologist appointed new chair of SMC
7 October 2016 - One of Scotland’s leading rheumatologists has been appointed as the next chair of the SMC. ...
Posted by Michael Wonder on 09 Oct 2016
Personal health spending: boom in vitamins, supplements, painkillers
7 October 2016 - Almost a third of personal health spending is on vitamins, supplements, over-the-counter painkillers and other unsubsidised ...
Posted by Michael Wonder on 09 Oct 2016
Guild submission to Pharmacy Review
5 October 2016 - The Pharmacy Guild of Australia has lodged its submission in response to the Review of Pharmacy ...
Posted by Michael Wonder on 09 Oct 2016
NICE backs use of Forxiga in triple therapy for diabetes
7 October 2016 - NICE has now published final draft guidelines endorsing NHS use of AstraZeneca's Forxiga for treating type ...
Posted by Michael Wonder on 09 Oct 2016
Thousands of European melanoma patients lack access to new drugs
7 October 2016 - More than a quarter of European patients with advanced melanoma lack access to new treatments that ...
Posted by Michael Wonder on 07 Oct 2016
CADTH calls for patient input on a submission from Celopharma for Mifegymiso
6 October 2016 - CADTH is calling for patient input on a submission from Celopharma for its combination product Mifegymiso. ...
Posted by Michael Wonder on 06 Oct 2016
Wound care decision points to future direction of devices work
6 October 2016 - PHARMAC is entering a new phase of its national hospital medical device contracting, as it implements ...
Posted by Michael Wonder on 05 Oct 2016
Sitagliptin and sitagliptin with metformin hydrochloride in type 2 diabetes mellitus: additional benefit compared to sulphonylurea plus metformin hydrochloride
4 October 2016 - For other questions, an additional benefit has not been established. ...
Posted by Michael Wonder on 05 Oct 2016
Saxagliptin and saxagliptin with metformin hydrochloride in type 2 diabetes mellitus: additional clinical benefits still not there
4 October 2016 - Study evaluations unsuitable for statements about the positive or negative effects over comparative therapies. ...
Posted by Michael Wonder on 04 Oct 2016
Costs and concerns in cancer care
5 October 2016 - Some recently developed anticancer drugs appear to be a major advance. ...
Posted by Michael Wonder on 04 Oct 2016
Crizotinib in NSCLC: new data are inconclusive
4 October 2016 - Increased proportion of treatment-change limits further interpretability so the results of the initial IQWiG evaluation shall continue. ...